Schonfeld Strategic Advisors LLC Glycomimetics Inc Transaction History

Schonfeld Strategic Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $45,662 - $66,676	-15,800 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $42,502 - $66,992	15,800 New	15,800 $60,000
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $1.92 Million - $2.4 Million	-140,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $1.46 Million - $1.91 Million	-99,575 Reduced 41.56%	140,000 $2.26 Million
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $3.38 Million - $5.33 Million	-210,425 Reduced 46.76%	239,575 $3.89 Million
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $526,593 - $862,790	-50,104 Reduced 10.02%	450,000 $7.56 Million
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $5.07 Million - $7.43 Million	500,104	500,104 $7 Million

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.